Evidence map›Paper›PMID 37029431›Full record

Trial reportActa obstetricia et gynecologica Scandinavica2023

Intraoperative use of tranexamic acid to reduce blood loss during cytoreductive surgery for advanced ovarian cancer: A randomized controlled clinical trial.

Xijun Yang, Mao Chai, Lingfang Xia, Zhiyong He, Xiaohua Wu, Jun Zhang

Registry-linked trialOpen access · diamondAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Acta obstetricia et gynecologica Scandinavica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04360629 (Efficacy and Safety of Tranexamic Acid in Cytoreductive Surgery for Ovarian Cancer), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04360629 nacompletednot on this map

Efficacy and Safety of Tranexamic Acid in Cytoreductive Surgery for Ovarian Cancer

TypeinterventionalSponsorJun ZhangRan2020 to 2021Enrolled151ConditionsAdvanced Ovarian CancerArmsTranexamic Acid, normal saline
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Xijun YangDepartment of Anesthesiology, Fudan University Shanghai Cancer Center, Shanghai, China.
Mao ChaiDepartment of Anesthesiology, Fudan University Shanghai Cancer Center, Shanghai, China.
Lingfang XiaDepartment of Oncological Gynecology, Fudan University Shanghai Cancer Center, Shanghai, China.
Zhiyong HeDepartment of Anesthesiology, Fudan University Shanghai Cancer Center, Shanghai, China.
Xiaohua WuDepartment of Oncological Gynecology, Fudan University Shanghai Cancer Center, Shanghai, China.
Jun ZhangDepartment of Anesthesiology, Fudan University Shanghai Cancer Center, Shanghai, China.ORCID 0000-0002-3197-0427
Fudan University Shanghai Cancer Center · CNShanghai Medical College of Fudan University · CN

Funding

Science and Technology Commission of Shanghai Municipality 20Y11906200
6 · The paper itself

Abstract

introductionTranexamic acid reduces blood loss and allogeneic transfusion requirements in various surgical procedures. The role of tranexamic acid during cytoreductive procedures in advanced ovarian cancer is not clear. MATERIAL AND

methodsThis was a single center randomized, controlled, three-armed clinical trial. A total of 150 ovarian cancer patients undergoing cytoreductive surgery were recruited and assigned to three groups (n = 50/group): the control group (normal saline), low-dose group (10 mg/kg bolus + 1 mg/kg continuous infusion of tranexamic acid), and high-dose group (20 mg/kg bolus + 5 mg/kg continuous infusion of tranexamic acid). The primary endpoint was intraoperative blood loss volume and total blood loss volume, and secondary endpoints included intraoperative blood transfusion volumes, vasoactive agent consumption, admission into the intensive care unit, and incidence of postoperative complications within postoperative 30 days. The study was registered at ClinicalTrials.gov ID: NCT04360629.

resultsThe patients in the high-dose group had less intraoperative (median [IQR]: 625.3 mL [343.5-1210.5]) and total blood loss volume (748.9 mL [292.2-1650.2]) than those in the control group (1015.5 mL [679.4-1015.5], p = 0.012; and 1700.7 mL [458.7-2419.8], p = 0.004, respectively). In contrast, the intraoperative (992.5 mL [539.0-1404.0], p = 0.874) and total blood loss volume (1025.0 mL [381.8-1819.9], p = 0.113) was not significantly reduced in the low-dose group when compared with the control group. Correspondingly, the relative risk of blood transfusion (RR [95% CI], 0.405 [0.180-0.909], p = 0.028) was reduced in the high-dose group and required less intraoperative noradrenaline (881.0 ± 438.3 mg) to maintain stable hemodynamics than the control group (1548.0 ± 349.8 mg, p = 0.001). Furthermore, compared with the control group, the two tranexamic acid groups had decreased intensive care unit admission rates (p = 0.016) without increasing the incidence of postoperative seizure, acute kidney injury, and thromboembolism.

conclusionsHigh-dose tranexamic acid is more effective in reducing blood loss and blood transfusion without increasing the risk of postoperative complications. The high-dose regime tended to have a better risk-benefit profile.

Indexed as

Antifibrinolytic AgentsOvarian NeoplasmsTranexamic AcidBlood Loss, SurgicalCarcinoma, Ovarian EpithelialCytoreduction Surgical ProceduresFemaleHumansPostoperative ComplicationsAntifibrinolytic AgentsTranexamic Acidblood losscomplicationscytoreductive surgeryovarian cancertranexamic acid

Identifiers

PMID37029431
PMCPMC10333657
OpenAlexW4362716886

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.